Humacyte, Inc. (NASDAQ:HUMA) Director Purchases $66,000.00 in Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction on Tuesday, April 8th. The shares were acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the purchase, the director now owns 91,207 shares in the company, valued at approximately $120,393.24. This trade represents a 121.34 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Humacyte Stock Performance

Shares of NASDAQ HUMA traded down $0.11 during midday trading on Tuesday, reaching $1.15. 3,106,805 shares of the company’s stock were exchanged, compared to its average volume of 3,478,426. Humacyte, Inc. has a 52-week low of $1.16 and a 52-week high of $9.97. The business’s fifty day moving average price is $3.24 and its two-hundred day moving average price is $4.33. The stock has a market capitalization of $166.57 million, a PE ratio of -0.86 and a beta of 1.62.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. The company had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million. Analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on HUMA. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research report on Wednesday, March 12th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Wednesday, March 26th. Finally, Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $13.71.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently added to or reduced their stakes in the business. Vontobel Holding Ltd. bought a new position in shares of Humacyte in the 4th quarter worth about $50,000. Petros Family Wealth LLC bought a new position in Humacyte during the 4th quarter valued at $50,000. Syon Capital LLC acquired a new position in shares of Humacyte in the 4th quarter worth approximately $54,000. Brookstone Capital Management bought a new stake in shares of Humacyte in the 4th quarter worth approximately $56,000. Finally, ACT Wealth Management LLC acquired a new stake in Humacyte during the fourth quarter valued at approximately $57,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.